Priothera
  • Home
  • About Us
  • Science
    • Our Clinical Candidate
    • Hematopoietic Stem Cell Transplantation
    • Our Pipeline
  • Publications
  • News
  • Contact Us
Select Page

S1P Receptor-1 agonist averts the De Novo Generation of Autoreactive T-cells in Murine Acute GVHD

https://priothera.com/wp-content/uploads/2021/11/new-publication-hs9-5-e613.pdf

Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis

https://priothera.com/wp-content/uploads/2020/09/Publication1.pdf

Recent Posts

  • Priothera Receives FDA clearance of Investigational New Drug (IND)
  • Priothera to present an abstract at the TANDEM Meetings / Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR – April 23-26 2022
  • Priothera Receives First Regulatory Approvals to Start a Global Pivotal Study with Mocravimod in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
  • Priothera Receives R&D Innovation Loan from Bpifrance
  • Priothera presents at EBMT conference March 20-23

Recent Comments

    Contact Us

    Priothera Ltd

    88 Harcourt Street, Dublin 2,
    D02 DK18, Ireland

    Priothera SAS France

    57 Avenue Général de Gaulle
    68300 Saint-Louis, France

    

    © Priothera Ltd. 2020